Skip to main content Help with accessibility Skip to main navigation


This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and Criteria for Categorisation of Medicines

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.


Date Added: 24 - May - 2018

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TIOTROPIUM inhalation (Spiriva Respimat®▼) for asthma in children and young people < 18 years of age.

Body System:
Date Added: 01 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends the prescribing of TIOTROPIUM inhaler (Spiriva® Respimat®) as an option for patients with poorly controlled asthma who are already on a maintenance dose of inhaled corticosteroid plus a long-acting beta2 agonist inhaler.

Body System: